Vaxxinity (VAXX) Stock Price, News & Analysis

Company Overview

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Key Stats

• Today's Range: $0.00 to $0.06
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $1.05
• Volume: 238,736 shs
• Average Volume: 689,864 shs
• Market Capitalization: $25,349.60
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VAXX Stock Analysis - Frequently Asked Questions

How have VAXX shares performed this year?

Vaxxinity's stock was trading at $0.85 at the beginning of the year. Since then, VAXX shares have decreased by 100.0% and is now trading at $0.0002.
View the best growth stocks for 2024 here.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) posted its earnings results on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16).

When did Vaxxinity IPO?

Vaxxinity (VAXX) raised $90 million in an IPO on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Vaxxinity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxxinity investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Rivian Automotive (RIVN) and Tesla (TSLA).

Company Calendar

• Last Earnings: 3/27/2023
• Today: 12/27/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VAXX
• CUSIP: N/A
• CIK: 1851657
• Web: www.vaxxinity.com
• Phone: 254-244-5739
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $70,000.00
• Price / Sales: 0.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 126,748,000
• Free Float: 45,553,000
• Market Cap: $25,349.60
• Optionable: Not Optionable
• Beta: 0.36